Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Washington State Mandate Will Raise Prescription Drug Costs for State Programs, Employers, Unions

By Drug Discovery Trends Editor | March 12, 2015

A bill (S.B. 5857) in the Washington legislature would force employers, unions, taxpayers, and public programs to pay drugstores more for prescription drugs, the Pharmaceutical Care Management Association (PCMA) said today.
 
A fiscal analysis by the Office of Financial Management asserts that just one provision of the bill could increase costs to Medicaid, the Public Employees Benefits delivery system and consumers by up to $113 million annually.  The analysis did not factor in the additional costs the mandate would impose on local employers and unions that offer prescription drug benefits.
 
S.B. 5857 requires public programs, employers and unions to pay top dollar for prescription drugs even when more affordable alternatives are available.  The fiscal analysis states that the bill could “significantly” increase costs, make plans “less effective at controlling costs” and “reduce the incentive for pharmacists to purchase the least expensive pharmaceutical available.”
 
“Considering how much this raises costs for state programs one can only imagine the impact it will have on local employers that offer benefits,” said PCMA President and CEO Mark Merritt. “Despite its costs, the bill offers no clear upside for consumers, either.” 
 
Specifically, S.B. 5857 would: 
• Force employers, unions, consumers and public programs to pay drugstores more for prescription drugs. 
• Reduce the incentive for pharmacists to purchase the least expensive pharmaceutical available. 
• Grant unprecedented legal authority empowering the Office of the State Insurance Commissioner to undermine contract agreements between plans and drugstores.
 
Source: Pharmaceutical Care Management Association

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE